- Home
- MVO vs CUE Comparison
MVO vs CUE Comparison
Compare MVO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- CUE
- Stock Information
- Founded
- MVO 2006
- CUE 2014
- Country
- MVO United States
- CUE United States
- Employees
- MVO N/A
- CUE N/A
- Industry
- MVO Oil & Gas Production
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MVO Energy
- CUE Health Care
- Exchange
- MVO Nasdaq
- CUE Nasdaq
- Market Cap
- MVO 94.2M
- CUE 77.3M
- IPO Year
- MVO N/A
- CUE 2018
- Fundamental
- Price
- MVO $8.18
- CUE $1.01
- Analyst Decision
- MVO
- CUE Strong Buy
- Analyst Count
- MVO 0
- CUE 5
- Target Price
- MVO N/A
- CUE $5.00
- AVG Volume (30 Days)
- MVO 55.1K
- CUE 354.9K
- Earning Date
- MVO 01-01-0001
- CUE 11-14-2024
- Dividend Yield
- MVO 17.46%
- CUE N/A
- EPS Growth
- MVO N/A
- CUE N/A
- EPS
- MVO 1.46
- CUE N/A
- Revenue
- MVO N/A
- CUE $9,532,000.00
- Revenue This Year
- MVO N/A
- CUE $105.39
- Revenue Next Year
- MVO N/A
- CUE N/A
- P/E Ratio
- MVO $7.29
- CUE N/A
- Revenue Growth
- MVO N/A
- CUE 149.53
- 52 Week Low
- MVO $8.85
- CUE $0.45
- 52 Week High
- MVO $13.95
- CUE $3.20
- Technical
- Relative Strength Index (RSI)
- MVO 36.39
- CUE 41.73
- Support Level
- MVO $8.36
- CUE $0.92
- Resistance Level
- MVO $8.38
- CUE $1.22
- Average True Range (ATR)
- MVO 0.33
- CUE 0.12
- MACD
- MVO -0.04
- CUE 0.00
- Stochastic Oscillator
- MVO 13.16
- CUE 29.03
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These oil and gas properties include producing oil and gas wells.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.